ASLN
Income statement / Annual
Last year (2023), ASLAN Pharmaceuticals Limited's total revenue was $12.00 M,
and the percentage change from the previous year is not available.
In 2023, ASLAN Pharmaceuticals Limited's net income was -$44.22 M.
See ASLAN Pharmaceuticals Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$12.00 M |
$0.00 |
$0.00 |
$0.00 |
$3.00 M |
$0.00 |
$0.00 |
$11.49 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$348.50 K
|
$331.75 K
|
$282.22 K
|
$297.76 K
|
$407.26 K
|
$241.56 K
|
$209.09 K
|
$124.37 K
|
$52.09 K
|
$0.00
|
| Gross Profit |
$11.65 M
|
-$331.75 K
|
-$282.22 K
|
-$297.76 K
|
$2.59 M
|
-$241.56 K
|
-$209.09 K
|
$11.36 M
|
-$52.09 K
|
$0.00
|
| Gross Profit Ratio |
0.97
|
0
|
0
|
0
|
0.86
|
0
|
0
|
0.99
|
0
|
0
|
| Research and Development Expenses |
$42.50 M
|
$38.00 M
|
$22.02 M
|
$9.31 M
|
$16.59 M
|
$31.83 M
|
$30.62 M
|
$13.10 M
|
$6.22 M
|
$4.50 M
|
| General & Administrative Expenses |
$13.24 M
|
$9.88 M
|
$11.83 M
|
$7.17 M
|
$8.51 M
|
$10.51 M
|
$9.33 M
|
$6.92 M
|
$6.61 M
|
$2.82 M
|
| Selling & Marketing Expenses |
-$348.50 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.89 M
|
$9.88 M
|
$11.83 M
|
$7.17 M
|
$8.51 M
|
$10.51 M
|
$9.33 M
|
$6.92 M
|
$6.61 M
|
$2.82 M
|
| Other Expenses |
-$11.13 K
|
$356.56 K
|
$0.00
|
$758.75 K
|
$23.07 M
|
$244.59 K
|
-$235.83
|
-$0.00
|
-$40.33 K
|
$5.46 K
|
| Operating Expenses |
$55.39 M
|
$47.88 M
|
$33.85 M
|
$16.48 M
|
$48.17 M
|
$42.35 M
|
$39.94 M
|
$20.02 M
|
$12.84 M
|
$7.31 M
|
| Cost And Expenses |
$55.74 M
|
$47.88 M
|
$33.85 M
|
$16.48 M
|
$48.58 M
|
$42.35 M
|
$39.94 M
|
$20.14 M
|
$12.84 M
|
$7.31 M
|
| Interest Income |
$404.98 K
|
$354.46 K
|
$219.00
|
$592.00
|
$150.61 K
|
$268.33 K
|
$370.59 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$4.33 M
|
$3.68 M
|
$1.86 M
|
$1.25 M
|
$901.61 K
|
$491.90 K
|
$425.27 K
|
$521.51 K
|
$986.93 K
|
$295.40 K
|
| Depreciation & Amortization |
$348.50 K
|
$331.75 K
|
$282.22 K
|
$297.76 K
|
$444.41 K
|
$241.56 K
|
$209.09 K
|
$76.00 K
|
$48.91 K
|
$24.85 K
|
| EBITDA |
-$43.39 M |
-$47.61 M |
-$32.04 M |
-$15.72 M |
-$45.76 M |
-$41.44 M |
-$40.07 M |
-$8.41 M |
-$12.29 M |
-$7.04 M |
| EBITDA Ratio |
-3.62
|
0
|
0
|
0
|
-15.25
|
0
|
0
|
-0.73
|
0
|
0
|
| Operating Income Ratio |
-3.64
|
0
|
0
|
0
|
-15.19
|
0
|
0
|
-0.75
|
0
|
0
|
| Total Other Income/Expenses Net |
-$342.75 K
|
-$2.97 M
|
$2.26 M
|
-$487.99 K
|
-$986.28 K
|
$176.91 K
|
-$767.73 K
|
-$289.50 K
|
-$1.14 M
|
-$49.52 K
|
| Income Before Tax |
-$44.08 M
|
-$51.28 M
|
-$31.59 M
|
-$16.97 M
|
-$46.66 M
|
-$42.17 M
|
-$40.71 M
|
-$9.00 M
|
-$13.33 M
|
-$7.36 M
|
| Income Before Tax Ratio |
-3.67
|
0
|
0
|
0
|
-15.55
|
0
|
0
|
-0.78
|
0
|
0
|
| Income Tax Expense |
$132.67 K
|
$99.22 K
|
$3.12 M
|
$934.92 K
|
$408.00 K
|
$14.44 K
|
-$342.46 K
|
$0.00
|
$500.03 K
|
$0.00
|
| Net Income |
-$44.22 M
|
-$51.38 M
|
-$34.71 M
|
-$17.91 M
|
-$47.07 M
|
-$42.19 M
|
-$40.71 M
|
-$9.00 M
|
-$13.33 M
|
-$7.36 M
|
| Net Income Ratio |
-3.68
|
0
|
0
|
0
|
-15.69
|
0
|
0
|
-0.78
|
0
|
0
|
| EPS |
-67.25 |
-92 |
-66.5 |
-58.25 |
-181.25 |
-176 |
-204.5 |
-43.25 |
-151.25 |
-720.25 |
| EPS Diluted |
-67.25 |
-92 |
-66.5 |
-58.25 |
-181.25 |
-176 |
-195.5 |
-43.25 |
-151.25 |
-720.25 |
| Weighted Average Shares Out |
$657.99 K
|
$557.96 K
|
$521.09 K
|
$307.56 K
|
$259.83 K
|
$239.58 K
|
$199.08 K
|
$208.12 K
|
$88.03 K
|
$10.22 K
|
| Weighted Average Shares Out Diluted |
$657.99 K
|
$557.96 K
|
$521.09 K
|
$307.56 K
|
$259.83 K
|
$239.58 K
|
$208.12 K
|
$208.12 K
|
$88.03 K
|
$10.22 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
